Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1 to 50 of 110 results for anticoagulation

  1. Venous thromboembolic diseases: diagnosis, management and thrombophilia testing (NG158)

    This guideline covers diagnosing and managing venous thromboembolic diseases in adults. It aims to support rapid diagnosis and effective treatment for people who develop deep vein thrombosis (DVT) or pulmonary embolism (PE). It also covers testing for conditions that can make a DVT or PE more likely, such as thrombophilia (a blood clotting disorder) and cancer.

  2. Atrial fibrillation: diagnosis and management (NG196)

    This guideline covers diagnosing and managing atrial fibrillation in adults. It includes guidance on providing the best care and treatment for people with atrial fibrillation, including assessing and managing risks of stroke and bleeding.

  3. Andexanet alfa for reversing anticoagulation from apixaban or rivaroxaban (TA697)

    Evidence-based recommendations on andexanet alfa (Ondexxya) for reversing anticoagulation form apixaban or rivaroxaban in adults with life-threatening or uncontrolled bleeding.

  4. Atrial fibrillation (QS93)

    This quality standard covers identifying and managing atrial fibrillation (including paroxysmal, persistent and permanent atrial fibrillation, and atrial flutter) in adults (aged 18 and over). It describes high-quality care in priority areas for improvement.

  5. Venous thromboembolism in adults (QS201)

    This quality standard covers reducing the risk of venous thromboembolism (VTE) in people aged 16 and over who are in hospital. It also covers diagnosing and treating VTE in all people aged 18 and over. It describes high-quality care in priority areas for improvement.

  6. Andexanet alfa for reversing anticoagulation in people with intracranial haemorrhage (part review of TA697) [ID6335]

    In development [GID-TA11472] Expected publication date: 18 December 2024

  7. Intrapartum care for women with existing medical conditions or obstetric complications and their babies (NG121)

    This guideline covers care during labour and birth for women who need extra support because they have a medical condition or complications in their current or previous pregnancy. The guideline also covers women who have had no antenatal care. It aims to improve experiences and outcomes for women and their babies.

  8. Stroke Prevention in Atrial Fibrillation (AF) Protect and Perfect – Optimising anticoagulation treatment

    clinicians to Protect and Protect patients diagnosed with AF on appropriate anticoagulation therapy in line with NICE guidance, thereby...

  9. microINR for anticoagulation therapy (MIB257)

    NICE has developed a medtech innovation briefing (MIB) on microINR for anticoagulation therapy .

  10. A programme to introduce annual GP review for patients on warfarin with atrial fibrillation who display poor anticoagulation control

    Fibrillation (2014) and subsequent Quality Standard (2015) prompted the Anticoagulation Service within City Health Care Partnership to...

  11. Acute coronary syndromes (NG185)

    This guideline covers the early and longer-term (rehabilitation) management of acute coronary syndromes. These include ST-segment elevation myocardial infarction (STEMI), non-ST-segment elevation myocardial infarction (NSTEMI) and unstable angina. The guideline aims to improve survival and quality of life for people who have a heart attack or unstable angina.

  12. Blood transfusion (NG24)

    This guideline covers the assessment for and management of blood transfusions in adults, young people and children over 1 year old. It covers the general principles of blood transfusion, but does not make recommendations relating to specific conditions.

  13. Improving anticoagulation in patients with atrial fibrillation using the GRASP AF audit tool (part of the GRASP suite of tools delivered by PRIMIS in partnership with NHS England)

    being at high risk of stroke, based on the relevant recommendations for anticoagulation in NICE guidance for AF (NG196). This example...

  14. Stroke and transient ischaemic attack in over 16s: diagnosis and initial management (NG128)

    This guideline covers interventions in the acute stage of a stroke or transient ischaemic attack (TIA). It offers the best clinical advice on the diagnosis and acute management of stroke and TIA in the 48 hours after onset of symptoms.

  15. Rivaroxaban for the treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism (TA261)

    Evidence-based recommendations on rivaroxaban (Xarelto) for treating deep vein thrombosis and preventing a pulmonary embolism or another deep vein thrombosis in adults.

  16. Perioperative care in adults (NG180)

    This guideline covers care for adults (aged 18 and over) having elective or emergency surgery, including dental surgery. It covers all phases of perioperative care, from the time people are booked for surgery until they are discharged afterward. The guideline includes recommendations on preparing for surgery, keeping people safe during surgery and pain relief during recovery.

  17. Apixaban for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism (TA341)

    Evidence-based recommendations on apixaban (Eliquis) for treating and preventing recurrent deep vein thrombosis or pulmonary embolism in adults.

  18. Major trauma: assessment and initial management (NG39)

    This guideline covers the rapid identification and early management of major trauma in pre-hospital and hospital settings, including ambulance services, emergency departments, major trauma centres and trauma units. It aims to reduce deaths and disabilities in people with serious injuries by improving the quality of their immediate care. It does not cover care for people with burns.

  19. Heart valve disease presenting in adults: investigation and management (NG208)

    This guideline covers investigation and management of heart valve disease presenting in adults. It aims to improve quality of life and survival for people with heart valve disease through timely diagnosis and appropriate intervention.

  20. Dabigatran etexilate for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism (TA327)

    Evidence-based recommendations on dabigatran etexilate (Pradaxa) for treating and preventing deep vein thrombosis and pulmonary embolism in adults.

  21. Rivaroxaban for the prevention of stroke and systemic embolism in people with atrial fibrillation (TA256)

    Evidence-based recommendations on rivaroxaban (Xarelto) for preventing stroke and systemic embolism in adults with non-valvular atrial fibrillation.

  22. Proportion of patients admitted to hospital for stroke with a pre-existing diagnosis of atrial fibrillation, who were on anticoagulation

    stroke with a pre-existing diagnosis of atrial fibrillation, who were on anticoagulation Subject(s): Atrial fibrillation

  23. Proportion of patients admitted to hospital for stroke with a pre-existing diagnosis of atrial fibrillation, who were not on anticoagulation

    with a pre-existing diagnosis of atrial fibrillation, who were not on anticoagulation Subject(s): Atrial fibrillation

  24. Stopping anticoagulation after ablation: What is the clinical and cost effectiveness of stopping anticoagulation in people whose atrial fibrillation has resolved after ablation?

    Question Stopping anticoagulation after ablation: What is the clinical and cost effectiveness of stopping anticoagulation...

  25. Rivaroxaban for treating pulmonary embolism and preventing recurrent venous thromboembolism (TA287)

    Evidence-based recommendations on rivaroxaban (Xarelto) for treating pulmonary embolism and for preventing a further deep vein thrombosis or pulmonary embolism in adults.

  26. Stopping anticoagulation after resolution of postoperative atrial fibrillation: What is the clinical and cost effectiveness of stopping anticoagulation in people whose postoperative atrial fibrillation after cardiac surgery has resolved?

    Stopping anticoagulation after resolution of postoperative atrial fibrillation: What is the clinical and cost effectiveness of stopping...

  27. Screening secondary care patients for atrial fibrillation: The SOS-AF service

    CHA2DS2-VASc assessment tool and consider the risks and benefits of anticoagulation. Where appropriate, treatment is started before...

  28. In those patients with atrial fibrillation with a record of a CHA2DS2-VASc score of 2 or more, the percentage of patients who are currently treated with anticoagulation drug therapy

    or more, the percentage of patients who are currently treated with anticoagulation drug therapy Subject(s): Atrial fibrillation

  29. Anticoagulation and antiplatelet therapy: In adults with biological valve replacement, what effect does anticoagulation or antiplatelet therapy have on long-term valve function and outcomes?

    Question Anticoagulation and antiplatelet therapy: In adults with biological valve replacement, what effect does...

  30. Atrial fibrillation and heart valve disease: self-monitoring coagulation status using point-of-care coagulometers (the CoaguChek XS system) (DG14)

    Evidence-based recommendations on the CoaguChek XS system for self-monitoring coagulation status in adults and children. The recommendations originally included

  31. Improving patients time in range on warfarin

    aimed to safely manage patients according to NICE guidelines regarding anticoagulation. Patients on warfarin need tight control over...

  32. Atrial Fibrillation (AF) Holistic Care Pathway

    practice were chosen and incorporated locally. Examples include: Anticoagulation assessment with better uptake of DOAC. Address...

  33. Implementing point-of-care D-dimer tests for deep vein thrombosis (DVT)

    states that if a D-dimer test cannot be obtained within 4 hours, interim anticoagulation should be given. If a person has a low...

  34. Improving the care of patients discharged following a pulmonary embolism, in line with NICE Guidelines (NG158)

    about 2–8% in the 3 months following diagnosis. The benefit of early anticoagulation to improve mortality and decrease recurrent...

  35. Insights from the NHS: the adoption of self-monitoring coagulation status using point-of-care coagulometers (the CoaguChek XS system and the INRatio2 PT/INR monitor) for atrial fibrillation and heart valve disease

    Health Call INR service, was developed by the clinicians working in the anticoagulation clinic and the chief pharmacist. This ensured...

  36. Acute upper gastrointestinal bleeding in over 16s: management (CG141)

    This guideline covers how upper gastrointestinal bleeding can be effectively managed in adults and young people aged 16 years and older. It aims to identify which diagnostic and therapeutic steps are useful so hospitals can develop a structure in which clinical teams can deliver an optimum service for people who develop this condition.

  37. Apixaban for preventing stroke and systemic embolism in people with non-valvular atrial fibrillation (TA275)

    Evidence-based recommendations on apixaban (Eliquis) for preventing stroke and systemic embolism in adults with non-valvular atrial fibrillation.

  38. Safe and effective management of stroke prevention in atrial fibrillation

    comprises of anticoagulants, with clear evidence to support the fact that anticoagulation with vitamin K antagonists (VKAs) or direct...

  39. GreenLight XPS for treating benign prostatic hyperplasia (MTG74)

    Evidence-based recommendations on GreenLight XPS for benign prostatic hyperplasia.

  40. Aortic valve reconstruction with processed bovine pericardium (IPG604)

    Evidence-based recommendations on aortic valve reconstruction with processed bovine pericardium. This involves replacing a damaged aortic valve with a new valve made from chemically treated cow pericardium.

  41. Accelerated Implantable Cardiac Monitor (ICM) insertion for the detection of Atrial Fibrillation in Cryptogenic Stroke

    performed remotely by the cardiac physiology team. If AF was detected, anticoagulation therapy was initiated without delay by the nurse...

  42. What is the most clinical and cost-effective strategy, as identified by a consensus survey, for the perioperative management of anticoagulation treatment in people taking a vitamin K antagonist with a target international normalised ratio (INR) of more than 3 who need bridging therapy?

    identified by a consensus survey, for the perioperative management of anticoagulation treatment in people taking a vitamin K antagonist...

  43. Reducing the risk of stroke in AF: using the NICE PDA with patients not currently treated with anticoagulants

    Some practices initiated anticoagulation themselves, but others referred their patients to the secondary care...

  44. Various modes used to reinforce NICE guidance for venous thrombo-embolism prophylaxis

    technology services' helped publish a screen saver based reminder about the anticoagulation policy recommendations on all networked...

  45. Hip fracture: management (CG124)

    This guideline covers managing hip fracture in adults. It aims to improve care from the time people aged 18 and over are admitted to hospital through to when they return to the community. Recommendations emphasise the importance of early surgery and coordinating care through a multidisciplinary Hip Fracture Programme to help people recover faster and regain their mobility.

  46. Aortic valve reconstruction with glutaraldehyde-treated autologous pericardium for aortic valve disease (IPG769)

    Evidence-based recommendations on aortic valve reconstruction with glutaraldehyde-treated autologous pericardium for aortic valve disease in adults. This involves replacing the diseased part of the valve with some of the person’s own pericardium.

  47. Anticoagulation and antiplatelet therapy: What is the clinical and cost effectiveness of single or dual antiplatelet therapies or anticoagulants compared with placebo after transcatheter or surgical valve replacement (implantation) with biological prosthesis and after valve repair?

    Recommendation ID NG208/22 Question Anticoagulation and antiplatelet therapy: What is the clinical and cost effectiveness of single or

  48. Using implantable cardiac monitors to detect atrial arrhythmias (fibrillation/flutter) after cryptogenic stroke

    identifying the cause and initiating appropriate secondary prevention (anticoagulation in case of atrial fibrillation or AF) To increase...

  49. Dronedarone for the treatment of non-permanent atrial fibrillation (TA197)

    Evidence-based recommendations on dronedarone (Multaq) for treating non-permanent atrial fibrillation in adults.